ATE479439T1 - Parvovirus mit cpg-angereichertem genom zur krebstherapie - Google Patents

Parvovirus mit cpg-angereichertem genom zur krebstherapie

Info

Publication number
ATE479439T1
ATE479439T1 AT07025215T AT07025215T ATE479439T1 AT E479439 T1 ATE479439 T1 AT E479439T1 AT 07025215 T AT07025215 T AT 07025215T AT 07025215 T AT07025215 T AT 07025215T AT E479439 T1 ATE479439 T1 AT E479439T1
Authority
AT
Austria
Prior art keywords
parvovirus
cpg
genome
rat
cancer therapy
Prior art date
Application number
AT07025215T
Other languages
English (en)
Inventor
Zahari Raykov
Jean Rommelaere
Nathalia Giese
Marc Aprahamian
Original Assignee
Deutsches Krebsforsch
Univ Ruprecht Karls Heidelberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforsch, Univ Ruprecht Karls Heidelberg filed Critical Deutsches Krebsforsch
Application granted granted Critical
Publication of ATE479439T1 publication Critical patent/ATE479439T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT07025215T 2007-12-28 2007-12-28 Parvovirus mit cpg-angereichertem genom zur krebstherapie ATE479439T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07025215A EP2075003B1 (de) 2007-12-28 2007-12-28 Parvovirus mit CpG-angereichertem Genom zur Krebstherapie

Publications (1)

Publication Number Publication Date
ATE479439T1 true ATE479439T1 (de) 2010-09-15

Family

ID=39325477

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07025215T ATE479439T1 (de) 2007-12-28 2007-12-28 Parvovirus mit cpg-angereichertem genom zur krebstherapie

Country Status (8)

Country Link
US (2) US8535929B2 (de)
EP (1) EP2075003B1 (de)
JP (1) JP4934221B2 (de)
AT (1) ATE479439T1 (de)
CA (1) CA2710889C (de)
DE (1) DE602007008929D1 (de)
ES (1) ES2352534T3 (de)
WO (1) WO2009083202A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2266587A1 (de) * 2009-06-04 2010-12-29 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Onkolytische Virotherapie zur Vorbeugung von Tumorrezidiv
WO2011135393A1 (es) * 2010-04-27 2011-11-03 Universidad Manuela Beltran Vacuna biologica autologa contra el cancer
ES2531581T3 (es) * 2010-10-21 2015-03-17 Deutsches Krebsforschungszentrum Reorientación de parvovirus de rata H-1PV hacia células oncológicas mediante manipulación genética de su cápside
US20130129678A1 (en) 2011-11-17 2013-05-23 Zahari Raykov Co-administration of a parvovirus and a cytokine for therapy of pancreatic cancer
CA3017773A1 (en) * 2016-03-17 2017-09-21 Deutsches Krebsforschungszentrum Lung cancer therapy with a parvovirus
EP3655964A1 (de) * 2017-07-18 2020-05-27 Koninklijke Philips N.V. Zuordnung von codierten medizinischen wortschätzen

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465438B1 (en) * 1996-04-19 2002-10-15 Metin Colpan Nucleic acid vaccination for parvoviral infections
US6339068B1 (en) * 1997-05-20 2002-01-15 University Of Iowa Research Foundation Vectors and methods for immunization or therapeutic protocols
US7179456B2 (en) * 2003-04-30 2007-02-20 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Use of parvovirus for brain tumor therapy

Also Published As

Publication number Publication date
JP4934221B2 (ja) 2012-05-16
CA2710889C (en) 2015-08-04
JP2011507535A (ja) 2011-03-10
DE602007008929D1 (de) 2010-10-14
ES2352534T3 (es) 2011-02-21
US8535929B2 (en) 2013-09-17
US20130344034A1 (en) 2013-12-26
WO2009083202A1 (en) 2009-07-09
EP2075003A1 (de) 2009-07-01
US20110033425A1 (en) 2011-02-10
EP2075003B1 (de) 2010-09-01
US10098917B2 (en) 2018-10-16
CA2710889A1 (en) 2009-07-09

Similar Documents

Publication Publication Date Title
DK2431045T3 (da) Bugspytkirtelkræftterapi med en parvovirus
ATE479439T1 (de) Parvovirus mit cpg-angereichertem genom zur krebstherapie
Gao et al. High-level transgene expression in nonhuman primate liver with novel adeno-associated virus serotypes containing self-complementary genomes
Shan et al. Genomic characterization and high prevalence of bocaviruses in swine
MX2012001592A (es) Composicion para el tratamiento de la infección del virus de la hepatitis b.
ATE506443T1 (de) Verwendung einer nukleinsäure zur herstellung einer transgenen pflanze mit verbesserter toleranz gegenüber trockenheit
WO2006033995A3 (en) Thiazolidin-4-ones having anti-hepatitis b activity
WO2008118507A3 (en) Recombinant human factor ix and use thereof
BRPI0721984B8 (pt) interferon-2b peguilado (ifn-2b), seu método de preparo e de purificação, composição, bem como uso dos mesmos
WO2005042728A3 (en) Immortalized avian cell lines for virus production
WO2013039861A3 (en) Engineered nucleic acids and methods of use thereof
MX2019013276A (es) Virus de la enfermedad de newcastle y usos de los mismos.
DK1554301T3 (da) Dengue-vaccine med en fælles udeladelse af 30 nukleotider i Dengue-typerne 1's og 2's3'UTR
Verhoeven et al. Dahlia latent viroid: a recombinant new species of the family Pospiviroidae posing intriguing questions about its origin and classification
Li et al. Characterization of the complete mitochondrial genome of basidiomycete yeast Hannaella oryzae: intron evolution, gene rearrangement, and its phylogeny
DE602008004317D1 (de) Verbindungen zur behandlung von hepatitis c
WO2006124777A3 (en) Post-transcriptional regulation of gene expression in plants
Arastehfar et al. Corrigendum: comparison of 21-Plex PCR and API 20C AUX, MALDI-TOF MS, and rDNA sequencing for a wide range of clinically isolated yeast species: improved identification by combining 21-Plex PCR and API 20C AUX as an alternative strategy for developing countries
WO2006047301A3 (en) Parvovirus methods and compositions for killing neoplastic cells
Cai et al. Hepatitis B virus genotype A: design of reference sequences for sub-genotypes
Lv et al. Complete genomic sequence of maize rough dwarf virus, a Fijivirus transmitted by the small brown planthopper
WO2007014174A3 (en) Drug-resistant mutants of hepatitis c virus
WO2012103522A3 (en) Materials and methods for identifying patients susceptible to developing taxane induced neuropthy
Shi et al. Characterization of a Pestivirus H isolate originating from goats
Xue et al. Complete genomic sequence of Southern rice blacked-dwarf virus, a novel Fijivirus, from Vietnam

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2075003

Country of ref document: EP